Gables Capital Management’s Aptose Biosciences, Inc. APTO Stock Holding History

Gables Capital Management’s Portfolio APTO Stock Details APTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3	Closed	-$5K	–	367
2021 Q2	$5K	Hold	3	–	–	﹤0.01%	328
2021 Q1	$9K	Hold	3	–	–	﹤0.01%	325
2020 Q4	$7K	Hold	3	–	–	﹤0.01%	321
2020 Q3	$9K	Buy	+3	New	+$7.48K	0.01%	317
2019 Q3	–	Sell	-2	Closed	-$3K	–	365
2019 Q2	$3K	Hold	2	–	–	﹤0.01%	318
2019 Q1	$2K	Hold	2	–	–	﹤0.01%	337
2018 Q4	$2K	Hold	2	–	–	﹤0.01%	356
2018 Q3	$3K	Hold	2	–	–	﹤0.01%	348
2018 Q2	$4K	Buy	+2	New	+$3.19K	﹤0.01%	341

Other funds holding APTO

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $36.7M AUM 6.81% 1-Year Est. Return

Gables Capital Management's APTO Position: Q3 2021 in Review

Gables Capital Management sold out of Aptose Biosciences, Inc. (APTO) in Q3 2021, closing a stake of 3 shares — an estimated $5K sold.

Gables Capital Management first reported a position in APTO in Q2 2018 and held it in 9 quarters. The position peaked at $9K in Q1 2021. 64 funds tracked by Wall St. Rank hold APTO as of Q3 2021.

Gables Capital Management reported no remaining Aptose Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
Gables Capital Management sold 3 Aptose Biosciences, Inc. shares in Q3 2021, an estimated $5K.
Gables Capital Management first reported a position in Aptose Biosciences, Inc. in Q2 2018 and held it in 9 quarters.
Gables Capital Management's Aptose Biosciences, Inc. position peaked at $9K in Q1 2021.
64 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q3 2021.

Based on Gables Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.